Topical TYK2 inhibitor ameliorates psoriasis-like dermatitis via the AKT-SP1-NGFR-AP1 pathway in keratinocytes

Abstract

	•Topical TYK2 inhibitor alleviates psoriasis-like dermatitis.
	•Topical TYK2 inhibitor reduces psoriasis progression through restraining the inflammatory responses of keratinocytes.
	•The inhibition of TYK2 regulates the inflammatory response of keratinocytes through AKT-SP1-NGFR-AP1 pathway.

Keywords

inflammatory response / keratinocyte / psoriasis / topical treatment / TYK2 inhibitor

References

[1] Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323:1945-1960.

[2] Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Prim. 2016;2:16082.

[3] Diani M, Altomare G, Reali E. T cell responses in psoriasis and psoriatic arthritis. Autoimmunity Rev. 2015;14:286-292.

[4] Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397:1301-1315.

[5] Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263-271.

[6] Nogueira M, Puig L, Torres T. JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors. Drugs. 2020;80:341-352.

[7] Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397:754-766.

[8] O’Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012;36:542-550.

[9] Clark JD, Flanagan ME, Telliez JB. Discovery and development of janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57:5023-5038.

[10] Pasparakis M, Haase I, Nestle FO. Mechanisms regulating skin immunity and inflammation. Nat Rev Immunol. 2014;14:289-301.

[11] Roskoski R. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res. 2016;111:784-803.

[12] Kim HO. Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors. Arch Pharm Res. 2020;43:1173-1186.

[13] Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11:eaaw1736.

[14] Renauld JC. Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat Rev Immunol. 2003;3:667-676.

[15] Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445:648-651.

[16] Sabat R, Wolk K, Loyal L, Döcke W, Ghoreschi K. T cell pathology in skin inflammation. Semin Immunopathol. 2019;41:359-377.

[17] Katz HI. Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris: review of the literature and results of a survey sent to 100 dermatologists. J Am Acad Dermatol. 1997;37;S62-S68.

[18] Mason A, Mason J, Cork M, Hancock H, Dooley G. Topical treatments for chronic plaque psoriasis: an abridged Cochrane systematic review. J Am Acad Dermatol. 2013;69:799-807.

[19] Mitra A, Wu YH. Topical delivery for the treatment of psoriasis. Expert Opin Drug Deliv. 2010;7:977-992.

[20] Guo J, Zhang H, Lin W, Lu L, Su J, Chen X. Signaling pathways and targeted therapies for psoriasis. Signal Transduct Target Ther. 2023;8:437.

[21] Roskoski R. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis. Pharmacol Res. 2023;189:106642.

[22] Srivastava M, Baig MS. NOS1 mediates AP1 nuclear translocation and inflammatory response. Biomed Pharmacother. 2018;102:839-847.

[23] Vukic V, Callaghan D, Walker D, et al. Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer’s brain is mediated by the JNK-AP1 signaling pathway. Neurobiol Dis. 2009;34:95-106.

[24] Xie L, Lv J, Saimaier K, et al. The novel small molecule TPN10518 alleviates EAE pathogenesis by inhibiting AP1 to depress Th1/Th17 cell differentiation. Int Immunopharmacol. 2023;123:110787.

[25] Zenz R, Eferl R, Kenner L, et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature. 2005;437:369-375.

[26] Ahn SS, Yeo H, Jung E, Lim Y, Lee YH, Shin SY. FRA1:c-JUN:hDAC1 complex down-regulates filaggrin expression upon TNFα and IFNγ stimulation in keratinocytes. Proc Natl Acad Sci U S A. 2022;119;e2123451119.

[27] Novoszel P, Holcmann M, Stulnig G, et al. Psoriatic skin inflammation is promoted by c-Jun/AP-1-dependent CCL2 and IL-23 expression in dendritic cells. Embo Mol Med. 2021;13;e12409.

[28] Figueira TG, Dos Santos FV, Yoshioka SA. Development, characterization and in vivo evaluation of the ointment containing hyaluronic acid for potential wound healing applications. J Biomater Sci Polym Ed. 2022;33:1511-1530.

[29] Fang Z, Wang Y, Huang B, Chen X, Jiang R, Yin M. Depletion of G9A attenuates imiquimod-induced psoriatic dermatitis via targeting EDAR-NF-κB signaling in keratinocyte. Cell Death Dis. 2023;14:627.

[30] Dura B, Choi J, Zhang K, et al. scFTD-seq: freeze-thaw lysis based, portable approach toward highly distributed single-cell 3’ mRNA profiling. Nucleic Acids Res. 2019;47;e16.

[31] Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36:411-420.

[32] Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16:284-287.

[33] Wu T, Hu E, Xu S, et al. clusterProfiler 4.0:a universal enrichment tool for interpreting omics data. Innovation (Cambridge (Mass)). 2021;2:100141.

[34] Gangwar RS, Gudjonsson JE, Ward NL. Mouse models of psoriasis: a comprehensive review. J Invest Dermatol. 2022;142:884-897.

[35] Ports W, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol. 2013;169:137-145.

[36] Wrobleski ST, Moslin R, Lin S, et al. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J Med Chem. 2019;62:8973-8995.

[37] Catlett IM, Hu Y, Gao L, Banerjee S, Gordon K, Krueger JG. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2022;149:2010-2020.e2018.

[38] Waickman AT, Powell JD. mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol Rev. 2012;249:43-58.

[39] Arumugham VB, Baldari CT. cAMP: a multifaceted modulator of immune synapse assembly and T cell activation. J Leukoc Biol. 2017;101:1301-1316.

[40] Billi AC, Ma F, Plazyo O, et al. Nonlesional lupus skin contributes to inflammatory education of myeloid cells and primes for cutaneous inflammation. Sci Transl Med. 2022;14:eabn2263.

[41] Ma F, Plazyo O, Billi AC, et al. Single cell and spatial sequencing define processes by which keratinocytes and fibroblasts amplify inflammatory responses in psoriasis. Nat Commun. 2023;14:3455.

[42] Wang Z, Sun Y, Lou F, et al. Targeting the transcription factor HES1 by L-menthol restores protein phosphatase 6 in keratinocytes in models of psoriasis. Nat Commun. 2022;13:7815.

[43] Yang LT, Fan XL, Cui TT, Dang EL, Wang G. Nrf2 promotes keratinocyte proliferation in psoriasis through up-regulation of keratin 6, keratin 16, and keratin 17. J Invest Dermatol. 2017;137:2168-2176.

[44] Liang SC, Tan X, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006;203:2271-2279.

[45] Wolk K, Witte E, Warszawska K, et al. The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol. 2009;39:3570-3581.

[46] Dudakov JA, Hanash AM, van den Brink MRM. Interleukin-22:immunobiology and pathology. Annu Rev Immunol. 2015:747-785.

[47] Farina L, Minnone G, Alivernini S, et al. Pro nerve growth factor and its receptor p75NTR activate inflammatory responses in synovial fibroblasts: a novel targetable mechanism in arthritis. Front Immunol. 2022;13:818630.

[48] Jiang RD, Xu J, Zhang Y, et al. Ligustrazine alleviates psoriasis-like inflammation through inhibiting TRAF6/c-JUN/NF kappa B signaling pathway in keratinocyte. Biomed Pharmacother. 2022;150:113010.

[49] Iraci N, Diolaiti D, Papa A, et al. A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF. Cancer Res. 2011;71:404-412.

[50] Huang D, Li T, Wang L, et al. Hepatocellular carcinoma redirects to ketolysis for progression under nutrition deprivation stress. Cell Res. 2016;26:1112-1130.

[51] Hong I, Byun H, Lee J, et al. The tetraspanin CD81 protein increases melanoma cell motility by up-regulating metalloproteinase MT1-MMP expression through the pro-oncogenic Akt-dependent Sp1 activation signaling pathways. J Biol Chem. 2014;289:15691-15704.

[52] Jiang Q, Yang G, Xiao F, et al. Role of Th22 cells in the pathogenesis of autoimmune diseases. Front Immunol. 2021;12:688066.

[53] Papp KA, Bissonnette R, Gooderham M, et al. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a phase 2b randomized clinical trial. BMC Dermatol. 2016;16:15.

[54] Jensen LT, Attfield KE, Feldmann M, Fugger L. Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors. Ebiomedicine. 2023;97:104840.

[55] Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol. 2012;67:658-664.

[56] Boehncke WH, Schön MP. Psoriasis. Lancet (Lond, Engl). 2015;386:983-994.

[57] Meyer M, Ben-Yehuda Greenwald M, Rauschendorfer T, et al. Mouse genetics identifies unique and overlapping functions of fibroblast growth factor receptors in keratinocytes. J Cell Mol Med. 2020;24:1774-1785.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.